Trial Profile
A Phase II Study Evaluating the Association of Topotecan and Lapatinib in Early Recurrent (Less Than 12 Months) Ovarian or Peritoneal Cancer Patients After First Line of Platinum-Based Chemotherapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Sep 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Topotecan (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms TOPO-LAPA
- 04 May 2009 New trial record